NKILA and breast carcinoma: Conversely, silencing NKILA in the context of an adoptive cell therapy in a patient-derived xenograft model of breast cancer can reduce AICD in T lymphocytes and improve therapy efficacy by preventing tumor immune evasion (Huang et al. 2018).